Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.061
- Book/Share 15.3114
- PB 7.2249
- Debt/Equity 1.3022
- CurrentRatio 1.3693
- ROIC 0.1532
- MktCap 138213062300.0
- FreeCF/Share 7.9005
- PFCF 14.0403
- PE 23.2092
- Debt/Assets 0.4421
- DivYield 0.0279
- ROE 0.3171
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
| Resumed | GILD | BofA Securities | -- | Buy | -- | $109 | Dec. 10, 2024 |
| Upgrade | GILD | Leerink Partners | Market Perform | Outperform | $74 | $96 | Oct. 21, 2024 |
| Initiation | GILD | Bernstein | -- | Outperform | -- | $105 | Oct. 17, 2024 |
| Upgrade | GILD | Wells Fargo | Equal Weight | Overweight | $78 | $100 | Oct. 7, 2024 |
News
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
GILD
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Read More
Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?
ALNY,
BIIB,
GILD,
MRNA,
VRTX
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Positive
We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.
Read More
The Zacks Analyst Blog Uber, Comcast, Gilead Sciences and Onfolio Holdings
CMCSA,
GILD,
UBER
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Published: February 10, 2025 by: Zacks Investment Research
Sentiment: Neutral
Uber, Comcast, Gilead Sciences and Onfolio Holdings are included in this Analyst Blog.
Read More
3 Fabulous Dividend Stocks to Buy in February
ABBV,
AMGN,
GILD
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive
Published: February 09, 2025 by: The Motley Fool
Sentiment: Positive
February is the shortest month, but that doesn't mean income investors don't have much time to find great stocks. Three Motley Fool contributors believe they have identified fabulous dividend stocks to buy this month.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Mr. Daniel P. O'Day
- Employees 17600
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.